Breaking News Instant updates and real-time market news.

LMAT

LeMaitre

$35.92

0.36 (1.01%)

, MMSI

Merit Medical

$56.25

0.4 (0.72%)

08:36
08/07/18
08/07
08:36
08/07/18
08:36

Needham to hold a conference

3rd Annual MedTech 1:1 Conference will be held in Boston on August 7.

LMAT

LeMaitre

$35.92

0.36 (1.01%)

MMSI

Merit Medical

$56.25

0.4 (0.72%)

TTOO

T2 Biosystems

$6.09

0.74 (13.83%)

  • 07

    Aug

  • 08

    Aug

  • 14

    Aug

  • 15

    Aug

  • 13

    Sep

  • 27

    Sep

LMAT LeMaitre
$35.92

0.36 (1.01%)

06/25/18
LSCM
06/25/18
INITIATION
Target $45
LSCM
Buy
LeMaitre initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil initiated LeMaitre Vascular with a Buy rating and $45 price target, contending that its recent biologics-focused acquisitions give it rapidly growing niche products that its sales organization can cross-sell to its installed base of vascular surgeons to expand its "already successful business."
06/08/18
06/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) and Eli Lilly (LLY) were initiated with an Overweight at Cantor Fitzgerald. 2. LivaNova (LIVN) initiated with a Buy at Stifel. 3. Occidental Petroleum (OXY) and Chevron (CVX) were initiated with a Buy at Mizuho while ConocoPhillips (COP) and Exxon Mobil (XOM) were initiated with a Neutral. 4. LeMaitre (LMAT) resumed with a Buy at Roth Capital. 5. Savara (SVRA) initiated with an Outperform, sees 300% upside, says Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/18
ROTH
06/08/18
INITIATION
Target $38
ROTH
Buy
LeMaitre resumed with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of LeMaitre Vascular with a Buy rating and $38 price target, as he expects resumed sales-force expansion to drive organic growth in the near-term and thinks the company's Reddick divestiture could help fund an acquisition, which could be a catalyst.
04/26/18
04/26/18
UPGRADE
Target $40

Buy
LeMaitre upgraded to Buy amid 'excessive' selloff at Benchmark
As previously reported, Benchmark analyst Raymond Myers upgraded LeMaitre Vascular to Buy from Hold as he believes the 20% post-earnings selloff in the shares is "excessive." He attributes the Q1 earnings shortfall mainly to sales execution issues and thinks management has already taken the necessary steps to fix the problems, he tells investors. Myers, who sees plans to expand the sales force leading to accelerating revenue growth in 2019, set a $40 price target on LeMaitre shares.
MMSI Merit Medical
$56.25

0.4 (0.72%)

07/24/18
BRRR
07/24/18
NO CHANGE
Target $61
BRRR
Outperform
Merit Medical price target raised to $61 from $50 at Barrington
Barrington analyst Michael Petusky raised his price target on Merit Medical shares to $61 from $50 after the company's Q2 revenue topped his "Street-high" estimate and the company increased its FY18 guidance, stating that Merit "clearly continues to have a lot of momentum." Management still sees gross margins improving in 2018, but not at the level previously expected, Petusky additionally noted. He maintains an Outperform rating on Merit Medical.
07/24/18
NEED
07/24/18
NO CHANGE
Target $67
NEED
Buy
Merit Medical price target raised to $67 from $54 at Needham
Needham analyst Mike Matson raised his price target on Merit Medical to $67 and kept his Buy rating after its better than expected Q2 results. The analyst notes that organic revenue growth has improved relative to Q1 despite the difficult comps and gross margins grew 60bps, even though he expected a higher rate of expansion. Matson anticipates Merit Medical to further improve in the second half of 2018 as comps ease and continued product shortage at Terumo benefits the company. The analyst also cites the positive impact from the "recent accretive acquisitions, manufacturing efficiencies, and higher margin product launches".
07/24/18
ADAM
07/24/18
NO CHANGE
Target $70
ADAM
Buy
Merit Medical price target raised to $70 from $60 at Canaccord
Canaccord analyst Jason Mils raised his price target on Merit Medical to $70 from $60 following Q2 results. The analyst noted the company delivered solid upside to expectations and he sees strong momentum in the business. He sees multiple tailwinds that could drive more upside, including increasing operating leverage, solid trends in core businesses, and supply issues at a competitor. Mills reiterated his Buy rating on Merit Medical shares.
07/24/18
PIPR
07/24/18
NO CHANGE
Target $58
PIPR
Overweight
Merit Medical transition to sizable mid-cap player continues, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Merit Medical Systems' Q2 beat expectations and that while management lowered its full year adjusted gross margin outlook by about 100 basis points, they more importantly increased their organic revenue outlook by roughly 250 basis points at the mid-point of the range. The strength in the core business was broad-based across products and geographies, O'Brien tells investors in a research note. He notes that management anticipates benefiting from a competitor supply disruption during the remainder of the year but is taking a conservative approach to this opportunity. The analyst thinks Merit continues its transition to a sizable mid-cap player in the med tech industry. He keeps an Overweight rating on the shares with a $58 price target.
TTOO T2 Biosystems
$6.09

0.74 (13.83%)

05/30/18
HCWC
05/30/18
NO CHANGE
Target $14
HCWC
Buy
T2 Biosystems price target raised to $14 from $8.50 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for T2 Biosystems to $14 after the company announced receipt of market clearance from the FDA for the T2Bacteria panel for direct detection of bacterial species in human whole blood specimens. T2Bacteria could generate four times the volume seen with T2Candida, Selvaraju tells investors in a research note. He notes this is the first FDA-cleared test to identify sepsis-causing bacteria directly from whole blood. Importantly, T2Bacteria provides test results in approximately five hours, which is more than 2.5 days faster than blood culture-dependent tests, the analyst adds. He reiterates a Buy rating on T2 Biosystems.
06/01/18
LEER
06/01/18
UPGRADE
LEER
Outperform
T2 Biosystems upgraded to Outperform from Market Perform at Leerink
06/01/18
LEER
06/01/18
UPGRADE
Target $12
LEER
Outperform
T2 Biosystems upgraded to Outperform with $12 target at Leerink
Leerink analyst Puneet Souda upgraded T2 Biosystems to Outperform from Market Perform and raised his price target for the shares to $12 from $5. This week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B, Souda tells investors in a research note. He believes T2 is "highly underpenetrated" in its core markets, but feels it can now penetrate the broader $1.5B-$2.0B bacterial sepsis market with an immediate entry into the hospital emergency departments, which the analyst values at $300M
06/01/18
06/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying American is likely to reduce capacity starting in the post-labor day period, which should be well received by investors. 2. T2 Biosystems (TTOO) upgraded to Outperform from Market Perform at Leerink with analyst Puneet Souda saying this week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B. 3. Highwoods Properties (HIW) upgraded to Buy from Hold at Stifel with analyst John Guinee saying he believes the macro environment is changing to the positive for REITs. 4. Toyota (TM) upgraded to Outperform from Neutral at Daiwa. 5. RLJ Lodging Trust (RLJ) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she views the current valuation as attractive and sees a strong RevPAR outlook for 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFAM

Bright Horizons

$141.18

1.73 (1.24%)

04:59
06/20/19
06/20
04:59
06/20/19
04:59
Upgrade
Bright Horizons rating change  »

Bright Horizons upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

04:56
06/20/19
06/20
04:56
06/20/19
04:56
Initiation
Enable Midstream initiated  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHDX

Genomic Health

$54.26

-0.04 (-0.07%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Upgrade
Genomic Health rating change  »

Genomic Health upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

CACI

CACI

$206.19

2.03 (0.99%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SIGI

Selective Insurance

$76.39

0.24 (0.32%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Selective Insurance management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

RVNC

Revance

$11.57

0.09 (0.78%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Revance management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 10

    Jul

  • 11

    Jul

SMG

Scotts Miracle-Gro

$98.53

0.4 (0.41%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Scotts Miracle-Gro management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

AJG

Arthur J. Gallagher

$86.81

0.775 (0.90%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Arthur J. Gallagher management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

BGSF

BG Staffing

$17.46

0.37 (2.17%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
BG Staffing management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

PZZA

Papa John's

$49.15

0.13 (0.27%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Papa John's management to meet with BTIG »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 13

    Nov

SSW

Seaspan

$9.22

0.06 (0.66%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Seaspan management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

04:55
06/20/19
06/20
04:55
06/20/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 6/15 Jobless…

ASB

Associated Banc-Corp

$20.76

-0.1 (-0.48%)

, BFC

Bank First National

$71.11

-2.38 (-3.24%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Sandler O'Neill to hold a field trip »

Wisconsin Community Bank…

ASB

Associated Banc-Corp

$20.76

-0.1 (-0.48%)

BFC

Bank First National

$71.11

-2.38 (-3.24%)

BWB

Bridgewater Bancshares

$11.38

0.19 (1.70%)

CZWI

Citizens Community Bancorp

$10.83

(0.00%)

FBIZ

First Business Financial

$23.41

-0.09 (-0.38%)

ICBK

County Bancorp

$17.19

(0.00%)

NCBS

Nicolet Bankshares

$61.99

0.19 (0.31%)

WSBF

Waterstone Financial

$16.85

-0.01 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$54.89

0.23 (0.42%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
CVS Health participates in a conference call with Morgan Stanley »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

NXPI

NXP Semiconductors

$96.25

1.49 (1.57%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
NXP Semiconductors to hold a conference call »

Conference call to review…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 09

    Jul

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
UBS leisure/gaming analyst to hold an analyst/industry conference call. »

Leisure, Gaming &…

TAST

Carrols Restaurant

$8.44

-0.06 (-0.71%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Carrols Restaurant management to meet with Stephens »

Two Days of Meetings to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 13

    Nov

BJRI

BJ's Restaurants

$41.31

-1.29 (-3.03%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
BJ's Restaurants management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

CSL

Carlisle

$138.31

1.67 (1.22%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Carlisle management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jul

AEO

American Eagle

$17.82

0.13 (0.73%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
American Eagle management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEEV

Veeva

$169.88

2.665 (1.59%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Veeva management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

IDCC

InterDigital

$63.83

-0.8 (-1.24%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
InterDigital management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

04:55
06/20/19
06/20
04:55
06/20/19
04:55
General news
Breaking General news story  »

Week of 6/14 EIA Natural…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.